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Abstract
Neurobiological disorders have diverse manifestations and symptomology. Neurodegenerative 
disorders such as Alzheimer’s disease (AD) manifest late in life and are characterized by, among 
other symptoms, progressive loss of synaptic markers. Developmental disorders, such as autism 
spectrum, appear in childhood. Neuropsychiatric and affective disorders, such as schizophrenia 
and major depressive disorder, respectively, have broad ranges of age of onset and symptoms. 
However, all share uncertain etiologies, with opaque relationships between genes and 
environment. We propose a “Latent Early–life Associated Regulation” (LEARn) model, positing 
latent changes in expression of specific genes initially primed at the developmental stage of life. In 
this model, environmental agents epigenetically disturb gene regulation in a long–term fashion, 
beginning at early developmental stages, but these perturbations might not have pathological 
results until significantly later in life. The LEARn model operates through the regulatory region 
(promoter) of the gene, specifically through changes in methylation and oxidation status within the 
promoter of specific genes. The LEARn model combines genetic and environmental risk factors in 
an epigenetic pathway to explain the etiology of the most common, i.e., sporadic, forms of 
neurobiological disorders.
THE LEARn MODEL
Neurobiological disorders have diverse manifestations and symptomology. 
Neurodegenerative disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease 
(PD), usually appear late in life and are characterized by progressive loss of synaptic 
markers and cholinergic neurons in AD and nigrostriatal projection neurons in PD, both 
eventually resulting in dementia.1–3 Developmental disorders, such as autism spectrum 
(AS), usually manifest in childhood and are typified by symptoms such as difficulty in 
pragmatic communication and social interaction, repetitive and stereotyped movements, and 
perseveration on a limited range of interests.4 Neuropsychiatric disorders such as bipolar 
disorder and schizophrenia tend to appear in adolescence and early adulthood. Bipolar 
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disorder is associated with a cycling of depressive and manic/hypomanic symptoms.5 
Schizophrenia has a complex of symptoms that includes lack of affect, social withdrawal, 
hallucinations, and disordered thinking. Other disorders include major depressive disorder 
(MDD) and anxiety disorders, which have a broad range of age of onset and manifest as a 
severe and pervasive emotional state together with behavioral and somatic symptoms.
All of these disorders share genetic risk factors that have incomplete penetrance. It is 
possible to have a “pathogenic” allele and not develop the associated disorder The popular 
current model is a polygenic/multifactorial model that renders no single contributory factor 
either necessary or sufficient. It is, instead, the interaction of multiple agents that are 
presumed to lead to a disorder, with some potential for environmental input.
A useful categorization of disease progression divides disorders and diseases into a few 
general models. An acute disorder begins shortly after a trigger event has occurred (Fig. 1A) 
and progresses, ultimately (presuming that it is not fatal) being self–limiting, with 
restoration of function at end of the disease episode. Many infectious diseases, such as 
rubella, fall into this category. A chronic (Fig. 1B) disorder likewise clinically presents after 
a trigger has occurred. However, the chronic disorder remains active for an extended period, 
potentially throughout an organism’s lifespan. This model would likely fit several classes of 
disorder, such as emphysema. Latent (Fig. 1C–D) disorders do not quickly manifest 
symptoms after an initial etiologic “hit” occurs. Within latent disorders, two subtypes can be 
characterized. Long prodromal phase disorders (Fig. 1C) are characterized by a “one–hit” 
etiology. A single triggering event is sufficient to induce the disease state, which simply 
takes an appreciable amount of time to “build up” to a clinical level, this latency could be 
manifest as recurrent sporadic symptomatic periods, such as with herpes simplex virus 
infection, or a latent period followed by an extended symptomatic period, as with HIV 
infection “Two–hit” latency (Fig. 1D) is an etiology that begins with an initial event or 
condition that, in and of itself, is insufficient to produce a disease state. The first hit could be 
exposure to environmental toxins, heavy metals, nutritional deficiency, stress, or even 
inherited genetic or epigenetic substrate. Later in life, a second hit would occur that, in those 
organisms that had suffered the first hit, would lead to disease. However, in organisms that 
were not subject to the first hit, no disease would occur. This model makes the greatest 
allowance for “sporadic” appearance of a disorder, especially if, instead of being “two–hit”, 
it is actually “many–” or “n–hit”, where “n” can be any number of individual risk factors, 
each with the potential to instill or activate a latent alteration. The most well-characterized 
“n-hit” disorders would be cancers.
We propose that many neurobiological disorders, regardless of their symptomatic variety, 
share a fundamentally similar mechanistic etiology: “Latent Early–life Associated 
Regulation” or “LEARn”.6–8 Under LEARn, early–life stressors modify potential 
expression levels of disorder–associated genes in a latent fashion. Latent changes in these 
genes are maintained by epigenetic mechanisms such as DNA methylation, DNA oxidation, 
and chromatin reorganization. LEARn–modified genes may require multiple “hits” to 
express at pathological levels. This is similar to the “two–hit” model of oncology.9 Recent 
work on primates and rodents has led to the determination that early–life exposure to 
external stress agents, such as lead (Pb) may induce a short term upregulation of disease–
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associated genes, followed by a long latency period of “normal” levels of gene expression, 
but this period ends when disease–associated gene expression levels increase later in life 
(Fig. 2A, B).10, 11 In addition, oxidative DNA damage, as measured by the presence of 
Oxo8dG, remains low early in life but at some point is increased, potentially due to 
suppression of repair enzyme expression. This oxidation would contribute to overall 
epigenetic changes and influence expression of pathogenic genes, resulting in increase in 
expression levels of pathogenic genes (Fig. 2B).
LEARn also postulates that in the case of disorders with distinctive ages of onset the final 
“hit” may be normal large–scale changes in gene expression that occur at various stages of 
development, such as puberty (both onset and end) or onset of senescence. However, for 
disorders that do not have such a characteristic age of onset, “non–shared” environmental 
influences would act as a temporally proximal trigger. In addition, LEARn posits two 
categories of target genes, “LEARNed” and “unLEARNed”, which are structurally distinct 
from each other. These structural differences are in the primary DNA sequences of the gene, 
specifically in densities of CpG and GG dinucleotides.
In the LEARn model, environmental agents (e.g., heavy metals), agrichemicals (e.g., 
pesticides-containing water), intrinsic factors (e.g., alleles or inflammatory cytokines), and 
dietary factors (e.g., folate and cholesterol) and lifestyle habits (e.g., physical exercise) act at 
early developmental stages to alter gene regulation in a long–term fashion. These 
disturbances would not produce disease states on their own,7, 10 and even then only after a 
latent period that may last up to several years (Fig. 3). Similar hypotheses were developed in 
the 1980s by Barker and colleagues.12. However, Barker’s model is based on low birth 
weight and rapid childhood weight gain, without identifying a molecular mechanism. 
LEARn is based on the regulatory structure common to eukaryotic genes and on epigenetic 
processes operating at specific sites within the promoter (regulatory) region of specific 
genes. LEARn is consistent with the Barker model of fetal origins of adult disease. It is also 
consistent with the more recently detailed “DOHaD” (developmental origins of health and 
disease) model.13
LEARn, however, enlarges upon both of these models by providing specific biochemical and 
molecular pathways that can be directly tested. LEARn introduces an intermediate step 
between genotype and phenotype, specifically the “somatic epitype”, which is an 
epigenotype acquired after birth.8 Evidence for the somatic epitype includes changes in 
DNA methylation induced by maternal behavior.14 LEARn explains maintained latency as 
epigenetic modification of gene regulatory sequences. LEARn is similar to the proposals of 
Szyf et al.15 However, LEARn is not a toxicological model. We expand upon these other 
models by positing structurally “LEARNed” and “unLEARNed” gene regulatory sequences 
and by including DNA oxidation in addition to methylation as an latent epigenetic marker. 
LEARn addresses the “black box” of sporadic disorder origins by expanding upon our 
findings that, in addition to latency and epigenetics, expresion levels of specific transcription 
factors, such as stimulatory protein 1 (SP1), and changes in primary DNA sequence 
oxidation levels interacting with neighboring methylation sites make up testable physical 
sites of the model’s activity. In addition, we have determined that expression of critical 
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transcription factors, such as SP1, parallel expression levels of disease–associated genes in 
model disorders, such as β–amyloid precursor protein (APP).16
NEURODEGENERATIVE DISORDERS
Degenerative neurobiological disorders include diseases such as Parkinson’s disease and 
Alzheimer’s disease. These diseases have a significant genetic component. Longitudinal 
studies have shown disease concordance for PD of 77% in monozygotic twins and 22% in 
dizygotic twins; however, cross–sectional twin studies contradict these findings.17, 18 Twin 
studies of AD indicate concordance of 75%–80% in monozygotic twins and 26%–46% in 
dizygotic.19, 20 Nevertheless, the majority of AD and PD cases cannot be explained by 
autosomal inheritance, which account for less than 1%21 of PD and 5%2 of AD. Genes 
associated with PD include α–synuclein (SNCA),22 Catechol–O–methyl transferase 
(COMT),23 and microtubule–associated protein τ (MAPT),24, 25 Genes associated with 
AD include APP,26 apolipoprotein E (APOE),27 β–amyloid cleaving enzyme 1 (BACE1).
28 MAPT,25, 29 and the presenilins, 1 and 2 (PSEN1, PSEN2).30 However, many more 
genes have been associated with these disorders (Suppl. Table 1).
Environmental factors, such as nutritional imbalance, stress, and exposure to risk agents 
such as heavy metals (for AD)31 or pesticides (for PD)32 are implicated but also fail to 
completely explain disease incidence. Presentation of disease symptoms usually occurs in 
the absence of an immediate trigger, strongly suggesting a long latent period. Finally, there 
is growing evidence that many of these diseases may have “interlocking”; risk factors that 
contribute to one of these diseases and contribute to other neurodegenerative disorders, such 
as the involvement of α–synuclein, β–amyloid, and microtubule–associated protein τ in both 
AD and PD.33, 34
NEURODEVELOPMENTAL DISORDERS
Neurodevelopmental conditions have a highly sporadic nature characterized by genetic and 
environmental risk factors. These include schizophrenia and autism, both of which have 
distinctive ages of onset.35, 36 Genetic risk factors such as neuregulin–1 (NRG1)37 for 
schizophrenia and reelin (RELN) or fragile–X mental retardation protein (FMR1)38 for 
autism, are among the many that have been implicated (Suppl. Table 1). However, as is the 
case for neurodegenerative disorders, genetic risk factors are not certain indicators. 
Environmental risk factors for schizophrenia include complications at birth,39, 40 childhood 
viral infections of the CNS41 and maternal exposure to severe adverse life effects such as 
death of a close relative during pregnancy.42 Autism has been linked to greater paternal 
age43 and prenatal stress,44 among other factors.
OTHER NEUROPSYCHIATRIC DISORDERS
Incomplete penetrance extends to other conditions, including bipolar disorder, major 
depressive disorder, and obsessive–compulsive disorder. These disorders manifest at any age 
or life stage. There are several gene associations (Suppl. Table 1), such as brain–derived 
neurotrophic factor (BDNF)45 for bipolar disorder and the serotonin transporter protein 
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(SLC6A4) for major depressive disorder46 and obsessive–compulsive disorder.47 These 
associations have also been found to be “incomplete”. Likewise, strong environmental 
components have been recognized in the etiology of OCD, bipolar disorder, and major 
depressive disorder, such as advancing paternal age and bipolar disorder, parental bonding 
variation and OCD, and childhood parental loss and major depressive disorder.48–51
ALZHEIMER’S DISEASE AS A MODEL FOR IDIOPATHIC 
NEUROPSYCHIATRIC DISORDERS
From an epidemiological standpoint, AD could be considered sufficient to model many 
aspects of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. AD 
manifests late in adult life, and it is not clearly understood when the disease begins its 
progression, nor how long this process takes. Large longitudinal studies have concluded that 
significant risk for developing AD is established by early adulthood.52 While this has led 
some researchers to conclude that AD must be a genetic disorder, such a conclusion 
dismisses well–established environmental risk factors such as inflammation,53 cholesterol/
diet,54 head injury,55 and reduced midlife physical activity.56 Even taking into account the 
very–well established genetic risk factor of the APOEε4 genotype,27 the majority of AD 
cases are idiopathic. A unifying hypothesis for the etiology of AD must take into account 
both its neuropathological features and multiple environmental factors associated with AD.
BIOLOGICAL MECHANISM OF THE LEARn MODEL
Oxidation of DNA often occurs as oxidation of d–guanosine to oxo8d–guanosine. The 5’ 
“G” of a “GG” dinucleotide is a hot spot of such oxidation.57 This interferes with the DNA–
binding capacity of methyl CpG–binding protein (MeCP) to a methylated cytosine,58 
producing an “effective demethylation” due to oxidative damage of DNA.
Methylation in mammalian DNA usually is the addition of a methyl group to cytosine 
residues at CpG dinucleotides.58 This reaction is catalyzed by DNA methyltransferase 
(DNMT) enzymes.59 Hypomethylation in the promoter region leads to elevated gene 
expression, whereas hypermethylation results in decreased gene expression. Environmental 
stressors, including exposure to metals and dietary factors, may interfere with the 
methylation of CpG clusters, thus altering affinity with potential transcription factors 
proteins, such as MeCP and stimulatory protein 1 (SP1). The activity of DNMT is reduced 
by heavy metal (cadmium) exposure.60 Furthermore, heavy metals such as Pb are known to 
induce oxidative stress,61 oxidative stress modulates DNA methylation during malignant 
transformation.62 In addition, trace copper in drinking water has been shown to facilitate 
formation of Aβ plaque in rabbits,63, 64 although the specific pathway for this effect is not 
determined. Aluminum has been shown to induce Z–DNA conformation at CCG repeats.65
Histone acetylation is also likely to function in the LEARn process, with differences in 
acetylation occurring in response to DNA methylation or demethylation.66 This, of course, 
would involve chromatin remodeling. However, it is our contention that changes in DNA 
oxidation and methylation are the initial means through which LEARn effects arise in 
reaction to the environment.
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BIOCHEMICAL EVIDENCE FOR THE LEARn MODEL
A specific example of LEARn activity may involve the response of Alzheimer–associated 
genes to early–life exposure to the heavy metal lead Pb, although this is not to be taken to 
mean that Pb is an exclusive operator in the LEARn model. It is presented as a model agent 
known to influence both DNA methylation67 and oxidation.68 When Basha and colleagues 
introduced Pb–acetate into the drinking water of dams of infant rats at 20 days post–birth 
(Pb–E) and at 19 months of age (Pb–L), levels of brain Pb when all rats were sacrificed at 20 
months of age were the same between early–exposed (Pb–E and control rats but elevated in 
Pb–L animals. However, at the age of 20 months, the early–exposed (Pb–E rats’ APP 
expression levels and Aβ peptide levels increased to levels higher than those of control rats 
and likewise higher than levels found in Pb–L rats. Longitudinal assays of APP mRNA and 
Aβ peptide levels revealed that these end–of–life changes did not reflect a “chronic” 
condition. While there was a temporary increase in these markers, levels returned to normal 
levels when Pb was removed from their diet. When SP1–DNA binding was compared 
between Pb–E and control rats, this followed a similar trend to APP mRNA levels. SP1–
DNA interaction was elevated during initial Pb exposure but fell to normal levels after Pb 
was removed from the diet. Late in life, SP1–DNA interaction increased significantly above 
that seen in control animals. In addition, DNA oxidation levels were also measured at end of 
life, and it was determined that oxo–d8–GTP levels were elevated in Pb–E animals.10 It was 
also determined that Pb treatment of cell cultures did not alter enzymatic activity of the α–, 
β–, or γ–secretases that process APP through the amyloidogenic or non–amyloidogenic 
pathways. However, Pb did increase Aβ aggregation in vitro.69 This in vitro aggregation 
may have an in vivo counterpart in the discovery that water quality influences Aβ 
aggregation in rabbits,70 although in that case copper was specifically implicated.63 
Likewise, in humans, elevated concentrations of agrichemicals in surface water in April–July 
coincided with higher risk of birth defects in live births with last menstrual periods during 
those months.71
Cynomolgus monkeys were also exposed to Pb during the first year of life (Pb–E) and were 
sacrificed for brain tissue analysis at the age of approximate 23 years. Comparing Pb–E 
brains with control (non–exposed) monkeys revealed that Pb levels between the two groups 
were the same. On the other hand, APP and SP1 mRNA levels were significantly elevated 
(BACE1 levels were elevated, but p = 0.06) vs. controls. In addition, Pb–E monkeys had 
significantly higher levels of Aβ42 and Aβ40 in later life. Exposed monkeys also showed 
greater brain amyloid aggregation and more dense aggregates than did non–exposed 
monkeys.72 Finally, comparison of DNA methyltransferase activity in both rodent cells 
exposed short term to Pb and in the early–lifespan Pb–exposed monkeys showed that Pb 
exposure significantly reduced activity of this enzyme in both systems.72
It is particularly notable that SP1 is likely to be regulated in a LEARn fashion, given that 
SP1 binds to the human73–76, rhesus monkey77 and rat78 APP promoter and accelerates 
the production of APP mRNA.73, 74, 78 Location and frequency of SP1 sites are more 
similar between monkey and human than between either primate species and rodent.77 
Furthermore, SP1 regulates the expression of the MAPT gene.79 In addition, SP1 and APP 
mRNA levels closely follow each other over the life spans of mice and monkeys.16
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EPIDEMIOLOGICAL AND CLINICAL EVIDENCE FOR THE LEARn MODEL
A recent survey of twin pairs for AD with Lewy body dementia showed discordance in 90% 
of monozygotic twins.80 In a separate study, a pair of identical twins with discordant 
development of AD had been brought up in the same household and had similar career 
paths, both becoming chemical engineers. One twin developed AD, while the other did not. 
It was determined that DNA methylation levels were different from each other, with the AD 
twin having a lower level of methylation than the non�AD twin.81 This is, of course, not 
DNA methylation, but it does indicate that AD etiology may be influenced by other 
epigenetic pathways. Regarding disorders other than AD, an association between prenatal 
exposure to Pb and schizophrenia has also been reported.82, 83
In neurodevelopmental disorders, autism has been associated with DNA hypomethylation in 
parents.84 Schizophrenia has been associated with both hypomethylation of MB–COMT85 
and with hypermethylation of RELN.86 Aberrant methylation has been implicated in bipolar 
disorder.85, 87 In mood and anxiety disorders, there have been several associations raised 
with abnormal methylation.85, 87, 88 Likewise, hypermethylation of the gene for ribosomal 
RNA has been implicated in suicide.89 Likewise, epigenetic dysregulation has been 
observed near several genes involved in neuronal development in the brain in individuals 
with major psychosis.90
While the above clinical data demonstrate association between aberrant methylation states 
and disease, they do not necessarily show that disease–associated methylation or other 
epigenetic states have been acquired after prenatal imprinting. Acquisition of an aberrant 
epigenetic state would be necessary for LEARn–style etiology to apply. It has been recently 
determined that methylation levels for an individual person change over a period of a decade 
for 29% of an Icelandic cohort.91 This raises the possibility of disease–related, 
environmentally induced methylation states. In addition to lifespan changes in DNA 
methylation states in humans, delayed neurological response has been demonstrated in rats 
subjected to postnatal inflammation. The treatment resulted in increased susceptibility to 
seizure in adulthood.92 Combination of these various elements, i) differential methylation 
patterns in disease, ii) potential for post–natal changes in gene methylation in individuals, 
and iii) demonstrated induction of lifespan–delayed neurological symptoms in an animal 
model, indicate a reasonable epidemiological case for further investigation of LEARn as a 
general model of idiopathic neurobiological diseases.
“LEARned” VS. “unLEARned” GENES
Observed differences of response to early–life exposure to Pb may define a more general 
class of gene regulation in response to methylation and oxidation “availability”. When Wu et 
al performed high-throughput analysis of monkey mRNA with a human neurological 
microarray twenty–three different genes were determined to have altered expression between 
Pb-exposed and control monkeys.72 In addition, APP, BACE1, and SP1 mRNA levels were 
found by northern blot to be elevated in Pb–exposed monkeys. Of the 23 microarray 
analyzed genes, 6 were upregulated and 17 were downregulated. Sequences of these 26 total 
genes (table 1), were downloaded from the human genome project (build 34.3) from −3000 
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to +3000 bp from the +1 TSS. An additional 26 "non-responding" genes were randomly 
chosen from the same array (table 1) and sequences of −3000/+3000 were downloaded. 
Sequence groups were compared for cumulative CpG and GG content, in a sliding window 
of 200bp. This size of sliding window was chosen as an approximation of the length of DNA 
in a nucleosome plus linker length between nucleosomes.
When CpG density in this 200bp window was compared, four regions of significant 
difference were found (Fig. 4A). Two of these regions were within 500bp of the +1 TSS, 
while two other regions were more distal (near −1000 and −2300). Significant differences in 
“GG” doublets, hotspots for DNA oxidation,93 were found at around −250/−350, 
+250/+350, and near +500 (Fig. 4B). The sequence derived model was tested by comparing 
it to the sequences of an AD–associated gene that did not show a late–life change in 
expression after Pb exposure, specifically MAPT (Fig. 5). While the MAPT sequence was in 
agreement with the LEARn model in proximal regions (between −500 and +500), it showed 
differences in CpG density from “LEARned” genes in a more distal region of interest, 
specifically around −750/−1000 and around −2300 from +1 TSS. This would suggest that 
the LEARn model, if further validated would structurally tie both distal and proximal 
elements of gene regulation.
LEARn AND SPORADIC DISEASE: A TWO–HIT PATHWAY
APP protein, the Aβ peptide, and τ protein all appear in healthy individuals. Their mere 
presence is not a sign of active or incipient AD. Therefore, it stands to reason that AD and 
other idiopathic neurobiological diseases are likely to be “triggered” independently of the 
simple presence of any associated proteins. For AD, the LEARn model posits developmental 
triggering and latency of the APP gene until it is further triggered to express at pathological 
levels. What could trigger APP and Aβ peptides to be overproduced in sporadic cases of 
AD? LEARn proposes that the initial mechanism is primed early in life, at developmental 
stages. Sites of action for AD would be within the promoter of APP and other AD–
associated genes. The trigger would be maintained through epigenetic means, such as DNA 
methylation. It is also possible that genes with products protective against AD are likely to 
have altered methylation patterns due to environmental stress.
AD, since it usually appears in senescence, would be a “long–latent” condition, and its 
etiology would be that of a “two–hit” disorder, similarly to those found in currently accepted 
models of cancer etiology.94 In the case of AD, this second hit would be a broad spectrum 
of changes in gene expression, especially upregulation of inflammatory factors, which has 
been shown to be a function of normal aging, as has been increased oxidative DNA damage 
in the aged cortex and specific targeting of genes by such oxidative damage.95 
Environmental insults do not “intentionally” target AD–related genes in the brain. Instead, 
certain genes, by juxtaposition of CpG and GG sites with important normally active or 
inactive transcription factor sites, would be particularly vulnerable to the effects of 
environmental stresses that alter CpG methylation and G oxidation. Testing such changes 
could, in part, be done by microarray analysis of sporadic and familial AD. If these assays 
were longitudinal, individual expression profiles could be traced across a lifetime, permitting 
comparison of the same AD and non–AD individuals at multiple life stages.
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The LEARn model lies within theories of epigenetics and the epigenome, specifically 
adapted to the etiology of sporadic disorders of long latency. The epigenome, the collection 
of epigenetic markers associated with a specific individual organism’s genome,96 has 
specific epigenotypes, generated by modification of DNA methylation or oxidation, by 
changes in histone acetylation patterns, and by variations in the physical arrangement of 
chromosomal material.97 It is the expression of these epigenotypes, whether they be 
inherited by imprinting or acquired during life as somatic epitypes8, that contributes to 
development of sporadic neuropsychiatric diseases.
The epigenome is inherently less stable than the genome. The epigenome is subject to 
changes in epigenetic markers over time within an individual lifespan. When individuals 
were followed longitudinally over average periods of 11 and 16 years, both increases and 
decreases in the methylation of an individual person’s genome were found in a well–
characterized Icelandic sample set and in a cohort of families in Utah.91
FURTHER IMPLICATIONS OF LEARn
The LEARn model proposes environmentally–induced changes in DNA methylation and 
oxidative damage as a fundamental mechanism of pathogenesis in idiopathic sporadic 
diseases.68 These perturbations would be latent, not as immediately apparent in the same 
manner found in conventional toxic responses. Thus, reversal of the symptoms of acute 
exposure to environmental stressors, such as Pb or poor nutrition, would not necessarily 
entail no long–lasting repercussions for an environmental insult. Conventional anti–toxicity 
treatments would be insufficient, since removing the cause would not remove the effect. This 
could be epidemiologically tested. For example, bans enacted upon Pb in gasoline in 
previous decades significantly reduce levels of Pb in urban dwellers. However, the LEARn 
model would suggest that levels of AD would not be likely to decrease in response until 50–
60 years after the bans were enacted, when individuals would begin to reach ages at risk of 
sporadic late–onset AD but would not have suffered higher levels of childhood Pb exposure. 
It should be pointed out that the possibility of “latent sequelae” to asymptomatic exposure to 
Pb was raised over 30 years ago, although without a specific underlying mechanism.98
However, the potential exists that the latent sequelae modeled by LEARn have a longer 
reach than inducing late–life disease in an exposed individual. Several groups have recently 
raised the possibility that acquired characteristics may very well be heritable. This, 
possibility, of course, brings to mind the theories of Jean–Baptiste Lamarck, who posited a 
connection between environmental responses and heritable traits in evolution.99 An 
increasing body of evidence has begun to suggest the possibility of medically important 
heritable traits.100 Whitelaw’s group determined that the epigenetic methylation states of 
the mouse Axin gene and associated phenotypes were heritable across generations.101 
Anway and Skinner administered the fungicide vinclozolin to mice during gestation and 
determined that not only did the offspring develop latent disease but the F1 through F4 
generations of non–exposed offspring developed these same late–life disorders at a 
significant level.102 Skinner’s group further determined that alterations in DNA methylation 
accompanied the pathogenic changes.103 The implication of such work is that LEARn 
pathogenesis operating through altered DNA methylation may permanently instill greater 
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incidence of latent neuropsychiatric disease such as AD in the descendants of an exposed 
population.
Long–term latency suggests the possibility of biologically–based remediation. Changes in 
methylation and/or oxidative damage to DNA, lend towards potential solutions to a LEARn–
type environmental exposure. For example, fruit juices, such as concentrated apple juice, 
have been shown to reverse acute oxidative damage and be a useful source of S–adenosyl 
methionine, reversing hypomethylation in rats.104 Likewise, dietary melatonin 
supplementation reduced levels of Aβ in rat cerebral cortex.105 This suggests investigation 
of the use of appropriate dietary supplementation early in life as a prophylactic or treatment 
measure against possible latent response to environmental insult. In addition, exercise in rats 
has been shown to modulate the activity of mucosal betaine–homocysteine 
methyltransferase 2, potentially reducing aberrant methylation.106 This suggests the 
possibility that those lifestyle habits suspected to protect against AD, such as physical 
exercise,107 may work through remediation of early–life aberrant DNA methylation. The 
LEARn model is not only a useful framework for the study of idiopathic neurobiological 
disease, but it has further implications in personal and public health practices.
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Fig. 1. Models of disease progression
Disease progression usually follows one of four models. A) Acute disease. An etiologic 
agent or condition “single hit” (including a genetic mutation) takes immediate or near–term 
to exposure effect, resulting in loss of function that progresses to disease symptoms, which 
eventually recede. B) Immediate–trigger chronic disease. An etiologic agent or condition 
takes immediate or near–term to exposure effect, resulting in loss of function that progresses 
to disease symptoms, which continue throughout life, or at least for some considerable time. 
C) One–hit latent disease. An etiologic agent or condition imposes immediate or near–term 
effect, but the effects are subclinical for an extended period. Over time, loss of function 
increases to a pathological level without any further “hits” to the organism. D) Two–hit 
latent disease. An etiologic agent or condition affects an organism but does not result in a 
diseased state. This alteration is maintained through the organism’s lifespan without readily 
visible effect unless a second hit intrudes. This interacts with the “embedded effect” of the 
first to produce a disease state.
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Fig. 2. LEARn effected gene expression
Diagrammatic representation of expression levels for disease–associated genes according to 
the LEARn model based upon rodent and primate research.10, 11 A) Susceptible genes 
undergo an early–life exposure to a stress such as heavy metals, inadequate maternal care, or 
nutritional deficit. This may result in an acute increase in expression levels that quickly 
returns to “normal” expression. Later in life an additional trigger may affect genes. Those 
organisms that have been previously subject to the initial trigger experience a significant 
increase in expression levels of disease–associated genes, while genes in organisms not 
primed in such a manner do not. B) Schematic representation of pathologically–associated 
genes and DNA oxidation damage in relationship to LEARn. Shortly after exposure to initial 
trigger, genes associated with a disorder would experience alterations such as an increase in 
expression level, while overall DNA oxidation would not be perturbed early in life. Later in 
life, DNA oxidation would be perturbed, which would lead to activation of the promoters of 
disease–associated genes, leading to active disease.
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Fig. 3. The LEARn model
Schematic representation of LEARn–type disease progression. A gene or genes associated 
with a disorder may be subject to an environmental “first trigger”, such as exposure to Pb or 
ROS. This results in an epigenetically marked gene, through methylation, oxidative damage 
of DNA, and/or chromatin rearrangement. The epigenetically marked gene may undergo a 
temporary change in expression levels, but this returns to “normal” levels. If a secondary 
trigger, such as additional environmental insult or systemic changes in gene expression 
patterns associated with aging, further affects the gene(s), expression levels deviate from 
normal, resulting in a disease state. Dotted lines represent alternate pathways.
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Fig. 4. “LEARned” vs. “unLEARned” genes, CpG or GG density
Graphs of A) CpG or B) GG density of genomic DNA sequences from 26 monkey genes, of 
−3000 to +3000 bases around the +1 TSS in 200bp window. Sequences were chosen after 
microarray of mRNA or by Northern blotting of mRNA indicated alterations in expression 
levels 23 years after exposure to Pb (black line).72. These were compared to 26 genes with 
expression levels not altered 23 years after exposure to Pb (gray line). The “non–
responding” genes were selected at random from the same RNA array that determined the 
“responding” genes. Graphs depict standard error of the mean along the sequence of CpG or 
GG density. Regions where differences in CpG density in the selected window size were 
significant at p < 0.05 are indicated with brackets under the graphs.
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Fig. 5. Comparison of “unLEARned” MAPT gene with the LEARned gene model
The MAPT gene, which did not respond to early–life Pb, was chosen for comparison with 
the LEARned gene model. CpG densities in a 200bp running window were calculated. 
Regions where MAPT resembles “unLEARned” genes are indicated with arrows.
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Table 1
LEARned and randomly selected unLEARned genes.
Expression altered by early-
life–exposure to Pb
(LEARned)
Expression not altered
by early–life exposure
to Pb (unLEARned)
Upregulated Downregulated
aAPPa AP2M1 ADORA1 HLA-C
BACE1a ARGHDIA ANXA3 PEX5
CALM3 CAPN3 CALR NF2
HMOX2 CLTC CETP PCSK2
NR4A3 DAO CHRNA1 PEBP1
PLA2G2A DNM2 CRHR1 PITPNA
SDHA DRD1 DBH PLCG2
SP1a GDI2 EFNB3 POU4F1
STX7 GNB1 FABP5 PRKACA
HTR1B GABRA3 RABGGTA
IQGAP1 GABRG2 SCP2
KCNJ4 GDNF STXBP2
OPRD1 HK1 SYT1
OPRM1
RAB32
RAB5A
RAB5C
a
Determined by northern blot measurement
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